Table 3.

Impact of AKI on outcomes

VariableValue for groupa
Non-AKIAKI
Onset of AKI, mean days ± SDNA6 ± 2.6
Change in Scr, fold increase from baseline (median, IQR)1.3 (1.2, 1.5)*1.9 (1.4, 2.5)*
Scr at discharge, mg/dl (median, IQR)0.7 (0.5, 0.9)*1.1 (0.7, 1.5)*
Patients with Scr above baseline at dischargeNA19 (44)
Patients with 28-day mortality9 (5)Y7 (16)Y
LOS after VAN initiation (median, IQR)9 (7, 14)*13 (10, 23)*
LOS total (median, IQR)11 (8, 17)*15 (11, 23)*
  • a Where not otherwise noted, value is the no. (%) of patients. For non-AKI group, n = 184; for AKI group, n = 43. *, P value < 0.05, Wilcoxon-Mann-Whitney test; Y, P value < 0.05, chi-square test. NA, not applicable.